Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EPS (Weighted Average and Diluted) (2021 - 2025)

Krystal Biotech's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at $1.7 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 11.11% year-over-year to $1.7; the TTM value through Dec 2025 reached $6.84, up 128.0%, while the annual FY2025 figure was $6.84, 128.0% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $1.7 at Krystal Biotech, down from $2.65 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.08 in Q3 2023 and bottomed at -$1.99 in Q1 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.34 (2021), against an average of $0.08.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 168.92% in 2022 before it skyrocketed 3900.0% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.95 in 2021, then dropped by 29.47% to -$1.23 in 2022, then skyrocketed by 125.2% to $0.31 in 2023, then skyrocketed by 393.55% to $1.53 in 2024, then rose by 11.11% to $1.7 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EPS (Weighted Average and Diluted) are $1.7 (Q4 2025), $2.65 (Q3 2025), and $1.29 (Q2 2025).